Neuroendocrine abnormalities in recreational ecstasy (MDMA) users: Is it ecstasy or cannabis?

被引：19
|
作者：
Gouzoulis-Mayfrank, E [1 ]
Becker, S [1 ]
Pelz, S [1 ]
Tuchtenhagen, F [1 ]
Daumann, J [1 ]
机构：
[1] Rhein Westfal TH Aachen, Fac Med, Dept Psychiat & Psychotherapy, D-52074 Aachen, Germany
来源：
BIOLOGICAL PSYCHIATRY | 2002年 / 51卷 / 09期
关键词：
ecstasy; MDMA; cannabis; neurotoxicity; serotonin; d-fenfluramine;
D O I：
10.1016/S0006-3223(01)01306-3
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Background: The purpose of this study was to investigate neuroendocrine function in ecstasy (3,4-methylenedioxymethamphetamine = MDMA) users and controls. Methods: Prolactin response to d-fenfluramine was assessed in abstinent ecstasy users with concomitant use of cannabis only (n = 24, male/female 13/11) and in two control groups: healthy nonusers (n = 13, female) and exclusive cannabis users (n = 7, male). Results: Prolactin response to d-fenfluramine was slightly blunted in female ecstasy users. Both male user samples exhibited a weak prolactin response to d-fenfluramine, but this was weaker in the group of cannabis users. Baseline prolactin and prolactin response to d-fenfluramine were associated with the extent of previous cannabis use, Conclusions: Endocrinological abnormalities of ecstasy users may be closely related to their coincident cannabis use. Cannabis use may be an important confound in endocrinological studies of ecstasy users and should be looked for more systematically in future studies.
引用
收藏
页码：766 / 769
页数：4
相关论文
共 50 条
  • [1] Cannabis and Ecstasy/MDMA: Empirical Measures of Creativity in Recreational Users
    Jones, Katy A.
    Blagrove, M.
    Parrott, A. C.
    [J]. JOURNAL OF PSYCHOACTIVE DRUGS, 2009, 41 (04) : 323 - 329
  • [2] Cognitive deficits and cognitive normality in recreational cannabis and Ecstasy/MDMA users
    Parrott, A
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2003, 18 (02) : 89 - 90
  • [3] Psychological profile of abstinent recreational Ecstasy (MDMA) users and significance of concomitant cannabis use
    Daumann, J
    Pelz, S
    Becker, S
    Tuchtenhagen, F
    Gouzoulis-Mayfrank, E
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2001, 16 (08) : 627 - 633
  • [4] Striatal Iron Deposition in Recreational MDMA (Ecstasy) Users
    Coray, Rebecca C.
    Berberat, Jatta
    Zimmermann, Josua
    Seifritz, Erich
    Stock, Ann-Kathrin
    Beste, Christian
    Cole, David M.
    Unschuld, Paul G.
    Quednow, Boris B.
    [J]. BIOLOGICAL PSYCHIATRY-COGNITIVE NEUROSCIENCE AND NEUROIMAGING, 2023, 8 (09) : 956 - 966
  • [5] MDMA, cortisol, and heightened stress in recreational ecstasy users
    Parrott, Andrew C.
    Montgomery, Cathy
    Wetherell, Mark A.
    Downey, Luke A.
    Stough, Con
    Scholey, Andrew B.
    [J]. BEHAVIOURAL PHARMACOLOGY, 2014, 25 (5-6): : 458 - 472
  • [6] Cannabis and ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users
    Parrott, A. C.
    Milani, R. M.
    Gouzoulis-Mayfrank, E.
    Daumann, J.
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2007, 114 (08) : 959 - 968
  • [7] Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users
    A. C. Parrott
    R. M. Milani
    E. Gouzoulis-Mayfrank
    J. Daumann
    [J]. Journal of Neural Transmission, 2007, 114 : 959 - 968
  • [8] The effect of Ecstasy/MDMA use on psychiatric symptoms in recreational users
    Zwalf, O.
    Ford, T.
    Hayley, A.
    Stough, C.
    Downey, L.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S185 - S186
  • [9] The Prevalence, Intensity, and Assessment of Craving for MDMA/Ecstasy in Recreational Users
    Davis, Alan K.
    Rosenberg, Harold
    [J]. JOURNAL OF PSYCHOACTIVE DRUGS, 2014, 46 (02) : 154 - 161
  • [10] Ecstasy, cigarettes, and inverse pleasure: Nicotine use and abstinence symptoms in recreational ecstasy/MDMA users
    Parrott, AC
    Margetson, JK
    Kissling, C
    Thome, J
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2005, 19 (05) : A27 - A27
12345